Strategic Financing Advisory in Life Sciences
R&D-focused companies are in the DNA of FCF. Life Sciences is therefore a natural fit as one of our focus areas. Companies in this sector have unique financing requirements and must be addressed individually. For this reason, we have formed a team of highly diverse industry and investment banking experts to develop and execute the best individualized financing strategies for our Healthcare clients. The combined experience and skill set allows us to tackle every angle in the translation of a great technology into a sound financing story.
We work with innovative European Life Sciences companies with cutting-edge technologies from sectors such as:
- Biotechnoloy
- Medical Technology
- Health Technology (IT)
We thrive to address all aspects of the financing challenges, that companies face from the seed to the commercialisation phase. We consider the long-term financing strategy as an important success factor, rather than focusing only on the next financing round. Part of this approach is to explore financing options on a regional and international scale and the combination of all available financing instruments:
- Venture Capital
- Equity-Linked Structures
- Growth / Venture Debt
- Off-Balance Financing
WHAT WE DO
At FCF Life Sciences, we develop bespoke financing strategies and support our clients throughout the entire fundraising process and beyond:
Our experienced team of industry and banking experts form a unique platform to develop the best financing story together with our clients. We emphasise on a clear and easy to understand presentation of the technology, development plan, competitive positioning, market potential and financial model. With the broadest portfolio of Life Sciences and Capital Markets data bases, we also add value with in-depth market intelligence not only to the management, but also to the board and shareholders.
Our proprietary Life Sciences deal database allows us to identify all relevant investors fast and reliably. Based on exclusive investor information, we develop the most customized investor lists for Seed, Venture Capital and Growth/Crossover financing rounds, as well as PIPE and block trades.
We have vast experience in non-dilutive financing options for Life Sciences companies and a complete overview of the growth debt providers in the Healthcare sector. In addition, FCF Life Sciences is the leading advisor for growth debt financings from the European Investment Bank, e.g. European Growth Finance Facility (EGFF) and InnovFin – Infectious Diseases (IDFF).
We engage in capital markets research to identify financing trends in the Life Science sector and new Life Science investors early. Our FCF Life Sciences Research Series primarily focuses on the latest developments in the most relevant equity markets: Venture Capital, Initial Public Offerings (IPO) and Public Equity. The results of our research are also channelled to our proprietary Life Science deal data.
We maintain trusted relationships to leading institutional and strategic Healthcare investors as well as family offices in Europe, USA and Asia. Supported by our US and Asian partners, we can approach the right investors depending on our client’s situation.
We can rely on a deep network to Life Sciences specialists (e.g. legal, valuation, licensing and IPO investment banks in the USA and Europe) to execute a seamless 360-degree long-term financing strategy. Our goal is to create value by implementing the best financing options for our clients.
TEAM
Arno Fuchs
Chief Executive Officer
Dr. Mathias Schott
Director
Sebastian Sommer
Associate
Alexander Kuhn
Analyst
Dr. Alexandra Goll
Advisor
Claus Schalper
Advisor
Prof. Dr. Horst Domdey
Advisor
Enno Spillner
Advisor
FACTS & FIGURES
European Life Sciences team specialised in pre-IPO financing
PREFERRED PARTNERS
SELECTED TRANSACTIONS
Vasopharm GmbH
July 2019
[amount confidential]
AMW GmbH
November 2017
€ 25 million
numares AG
November 2017
€ 11 million
MagForce AG
August 2017
€ 35 million
Biofrontera AG
May 2017
€ 20 million
LIFE SCIENCES RESEARCH SERIES
We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our FCF Life Sciences Research Series focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:
Venture Capital Monitor
Monthly Venture capital activities in the European Life Sciences sector
Venture Capital ReportRecent Venture capital trends in the European Life Sciences sector
Public Equity MonitorRecent valuations of listed European Life Sciences companies
IPO ReportRecent IPO trends in the Life Sciences sector
NEWS & PRESS
FCF Life Sciences Venture Capital Monitor – 08/2020 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – 08/2020”. The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies,
FCT at 3rd ECP Summer Summit on September 17 – 18, 2020 – first digital European Chemistry Partnering
The 3rd ECP Summer Summit took place on September 17th and 18th 2020 for the first time as a two-day online event. FCF acted as Diamond Sponsor. More than 400 participants from 43 nations met
FCF Life Sciences Venture Capital Monitor – 07/2020 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – 07/2020”. The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies,
FCF Life Sciences Venture Capital Monitor – 06/2020 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – 06/2020”. The Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies,
FCF Life Sciences Public Equity Monitor 05/2020 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Public Equity Monitor – 05/2020”. The Public Equity Monitor, part of FCF Life Sciences Research Series, is the most detailed and
